In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Dermatology-focused biotech Menlo Therapeutics Inc. netted $127mm in an initial public offering of 8mm shares (including the overallotment) at $17. The company first planned to offer 5.7mm shares at a $14-16 range, but later upped that to 6.5mm shares at an anticipated price of $16-17.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?